Kura Oncology.
company in La Jolla, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 31
What's happening
Earlier this month
-
Kura Oncology is seeking an Investigational New Drug (IND) application for its drug candidate KO-7246.Some support1 report
-
Ionis Pharmaceuticals' RNA drug failed a study, while Eli Lilly invested in a spinout from Kura Oncology.Some support2 reports
-
Kura Oncology created Caspian Therapeutics for diabetes research, which is backed by Eli Lilly, with a meeting scheduled in Milan.Some support1 report
One to three months ago
-
Kura Oncology reported its earnings on Nasdaq on August 12, 2026. Kyowa Kirin announced it was funding Kura's program.Some support4 reports
-
Kura Oncology announced the publication of preclinical findings for ziftomenib, a drug that received FDA approval in 2025.Some support1 report
-
Kura Oncology filed an insider trading transaction disclosure with the SEC, and Jefferies Financial Group provided price targets for the company.Some support3 reports
-
FDA granted Breakthrough Therapy Designation to Ziftomenib and entered a global strategic collaboration agreement.Some support4 reports1 development inside
-
Kura Oncology and Syndax Pharmaceuticals are biopharmaceutical companies, and Trump-era tariffs are noted to be benefiting certain AI stocks.Some support1 report
Gone quiet
No new reports in 90+ days-
Marc Grasso was appointed CFO of Kyverna Therapeutics, following his previous roles at Kura Oncology, Morgan Stanley, and UBS.Speculative1 report
-
Amgen acquired Five Prime Therapeutics for $1.9 billion, and Carol A. Schafer was appointed to boards at Kura Oncology and OMass Therapeutics.Some support1 report
-
Kura Oncology participated in the Cantor Global Health Conference on August 28, 2025.Some support1 report
-
Kura Oncology is based in San Diego.Some support2 reports
-
Kura Oncology presented FIT-001 data on darlifarnib at the annual meeting of the American Society of Clinical Oncology.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Kura Oncology this week
News at the entities that move Kura Oncology most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Kura Oncology
-
Kyowa Kirin OperationalJefferies lowered Kyowa Kirin's stock rating on September 1, 2026, for the company headquartered in Tokyo.Moves Kura Oncology
-
Citigroup Mentioned togetherCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves Kura Oncology
-
Jefferies Financial Group Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Kura Oncology
-
University of Michigan OperationalConsumer Sentiment Index shows a disconnect from economic reality, leading critics to question the validity of the underlying economic data.Moves Kura Oncology
-
Wilson OperationalScott Wilson is the Chief of Staff for CARTA, based in Chattanooga.Moves Kura Oncology
Connections
The 18 strongest of 31, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Kura Oncology seeks regulatory approval and designation for its drug candidates from the FDA.
-
Troy Wilson Structural
Troy Wilson serves as the Chief Executive Officer of Kura Oncology.
-
Kyowa Kirin Operational
Kura Oncology and Kyowa Kirin maintain a strategic collaboration for joint development and commercialization of ziftomenib.
-
Nasdaq Structural
Kura Oncology is formally listed on the Nasdaq stock exchange for financial reporting.
-
Citigroup Mentioned together
Citigroup issued a market outperform rating on Kura Oncology.
-
SEC Structural
Kura Oncology is subject to mandatory insider trading disclosure requirements enforced by the SEC.
-
University of Michigan Operational
The two entities maintain an active, established collaboration focused on small molecule discovery research.
-
American Society of Clinical Oncology Operational
The two entities collaborated to present FIT-001 clinical trial data on darlifarnib.
Show all 18 connections
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides market coverage and price targets for Kura Oncology.
-
Eli Lilly and Company Transactional
Eli Lilly invested in a spinout originating from Kura Oncology.
-
Wilson Operational
Wilson questioned Kura Oncology's market share claims, indicating direct market scrutiny.
-
Benzinga Mentioned together
Benzinga, a financial news service, tracks and reports on Kura Oncology's stock rating.
-
Caspian Sea Shared context
Kura Oncology's research operations are situated within the geographic context of the Caspian Sea.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provided an overweight rating on Kura Oncology.
-
Milan Shared context
Kura Oncology presented data at the EHA Congress held in Milan.
-
MarketBeat Mentioned together
MarketBeat provides average stock ratings for Kura Oncology.
-
Blood Mentioned together
Kura Oncology published preclinical findings regarding the biological entity Blood.
-
San Diego Shared context
Kura Oncology is located and operates its headquarters in San Diego.
History
Events by the month they beganSeptember 2026
3 events- Kura Oncology is seeking an Investigational New Drug (IND) application for its drug candidate KO-7246.
- Ionis Pharmaceuticals' RNA drug failed a study, while Eli Lilly invested in a spinout from Kura Oncology.
- Kura Oncology created Caspian Therapeutics for diabetes research, which is backed by Eli Lilly, with a meeting scheduled in Milan.
August 2026
2 eventsJune 2026
8 events- Kura Oncology filed an insider trading transaction disclosure with the SEC, and Jefferies Financial Group provided price targets for the company.
- FDA granted Breakthrough Therapy Designation to Ziftomenib and entered a global strategic collaboration agreement.
- Kura Oncology and Syndax Pharmaceuticals are biopharmaceutical companies, and Trump-era tariffs are noted to be benefiting certain AI stocks.
- Marc Grasso was appointed CFO of Kyverna Therapeutics, following his previous roles at Kura Oncology, Morgan Stanley, and UBS.
- Amgen acquired Five Prime Therapeutics for $1.9 billion, and Carol A. Schafer was appointed to boards at Kura Oncology and OMass Therapeutics.
- Kura Oncology participated in the Cantor Global Health Conference on August 28, 2025.
- Kura Oncology is based in San Diego.
- Kura Oncology presented FIT-001 data on darlifarnib at the annual meeting of the American Society of Clinical Oncology.